Tech Transfer Roundup: NCI Licenses Leukemia, Brain Cancer Candidates To Vor, Connectyx
Executive Summary
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
You may also be interested in...
BridgeBio Pharma’s Pipeline Expansion Continues As Existing Portfolio’s Milestones Approach
The company already has more than 20 subsidiaries developing treatments for monogenic diseases and genetically defined cancers, but its deal-making pace has not slowed.
IP Commercializer PureTech Enters CAR-T With Vor BioPharma Start-Up
PureTech Health has moved into the hot area of CAR-T immuno-oncology by launching Vor BioPharma - but the IP commercializer isn't giving details on the start-up's novel chimeric antigen receptor T-cell therapy platform, or how it hopes to remove bottlenecks to the approach's use outside of B-cell cancers.
Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Need a specific report? 1000+ reports available
Buy Reports